- Home
- PK vs ZLAB Comparison
PK vs ZLAB Comparison
Compare PK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- ZLAB
- Stock Information
- Founded
- PK 1946
- ZLAB 2013
- Country
- PK United States
- ZLAB China
- Employees
- PK N/A
- ZLAB N/A
- Industry
- PK Real Estate Investment Trusts
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- ZLAB Health Care
- Exchange
- PK Nasdaq
- ZLAB Nasdaq
- Market Cap
- PK 2.1B
- ZLAB 3.6B
- IPO Year
- PK N/A
- ZLAB 2017
- Fundamental
- Price
- PK $11.21
- ZLAB $32.54
- Analyst Decision
- PK Hold
- ZLAB Buy
- Analyst Count
- PK 11
- ZLAB 5
- Target Price
- PK $12.85
- ZLAB $54.28
- AVG Volume (30 Days)
- PK 3.9M
- ZLAB 782.4K
- Earning Date
- PK 07-31-2025
- ZLAB 08-05-2025
- Dividend Yield
- PK 12.35%
- ZLAB N/A
- EPS Growth
- PK 45.67
- ZLAB N/A
- EPS
- PK 0.61
- ZLAB N/A
- Revenue
- PK $2,602,000,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- PK $2.49
- ZLAB $44.07
- Revenue Next Year
- PK $3.25
- ZLAB $49.13
- P/E Ratio
- PK $18.38
- ZLAB N/A
- Revenue Growth
- PK N/A
- ZLAB 43.72
- 52 Week Low
- PK $8.27
- ZLAB $16.01
- 52 Week High
- PK $16.23
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- PK 62.34
- ZLAB 40.19
- Support Level
- PK $10.50
- ZLAB $34.26
- Resistance Level
- PK $11.49
- ZLAB $35.72
- Average True Range (ATR)
- PK 0.33
- ZLAB 1.12
- MACD
- PK 0.09
- ZLAB -0.54
- Stochastic Oscillator
- PK 81.79
- ZLAB 3.83
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.